How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?

  • Question on Document

    Please could medical professionals with relevant experience consider the list of outcomes in the evidence generation plan and provide feedback comments?

Evidence generation plan for HTG10887 Digital platforms to support preparation before and rehabilitation after primary elective hip or knee replacement surgery: early-use assessment

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

1 Purpose of this document

NICE's assessment of digital platforms to support preparation before and rehabilitation after primary elective hip or knee replacement surgery recommends that the following digital platforms can be used during the evidence generation period:

  • for hip or knee replacement surgery:

    • mymobility

  • for hip replacement surgery:

    • GoWellHealth

  • for knee replacement surgery:

    • BPMpathway

    • Physitrack.

The other technologies that were assessed can only be used in research and are not covered in this plan.

This plan outlines the evidence gaps and what data needs to be collected for a NICE review of the technologies again in the future. It is not a study protocol but suggests an approach to generating the information needed to address the evidence gaps. Evidence generated through other study approaches will also be considered. For assessing comparative treatment effects, well-conducted randomised controlled trials are the preferred source of evidence.

The companies are responsible for ensuring that data collection and analysis take place. Support for evidence generation may be available through the National Institute for Health and Care Research Invention for Innovation product development award. Academic support may be available through groups such the NIHR HealthTech Research Centres.

NICE will withdraw all or part of the guidance if a company does not meet the conditions in section 4 on monitoring. After the end of the evidence generation period (3 years), the companies should submit the evidence to NICE in a format that can be used for decision making. NICE will review all the evidence and assess whether the technologies can be routinely adopted in the NHS.